J & J's 2019 financial report: total revenue: US $82 billion! Darzalex's full line power

On January 22, Johnson & Johnson announced its 2019 results, achieving a total revenue of US $82.059 billion, an increase of 0.6% year on year Among them, the revenue of pharmaceutical business segment is US $42.198 billion (+ 3.6%), the revenue of medical device business segment is US $25.963 billion (- 3.8%), and the revenue of consumer health business segment is US $13.898 billion (+ 0.3%) Compared with the stagnant growth of medical devices and consumer health care business in recent years, the pharmaceutical business sector is still the main driving force for Johnson & Johnson to maintain growth, while the two fastest growing disease sectors are autoimmune diseases (US $13.95 billion, + 6.3%), tumors (US $10.692 billion, + 8.6%) In terms of specific products, in 2019, Johnson & Johnson had 11 blockbuster drugs with sales of more than US $1 billion, seven of which were in the field of autoimmune diseases and tumors The U.S market of REMICADE (infliximab) is in the charge of Johnson & Johnson, but at present, there are biosimilars from hospita, MSD / Samsung bioepis and Pfizer that have been approved by FDA, and the first two drugs have been on the market, making REMICADE face fierce competition, so it can only maintain the market through price reduction and greater reimbursement compensation The U.S market revenue is nearly 7 billion US dollars from 2016 The peak value continued to decline to $4.38 billion in 2019, and the decline gradually increased Correspondingly, simponi, another TNF - α monoclonal antibody drug of Johnson & Johnson, has also been impacted by many other TNF - α biological analogues, and the sales growth in the past three years can only be kept in a low single digit Stelara (ulinuzumab) has achieved an amazing double-digit growth in the last three years By 2019, it has grown into a large drug with annual sales of 6.361 billion US dollars, and is expected to enter the top 10 of the world's best-selling drugs in 2019 (the threshold of the top 10 in 2018 is 6.7 billion US dollars) According to the sales forecast released by nature reviews drug discovery a few days ago, stelara will reach 7.241 billion US dollars in 2020, ranking 7th in the top 10 best selling drugs list in the world It can be said that stellara plays a mainstay role in the whole pharmaceutical business segment of Johnson & Johnson, especially in the autoimmune disease drug market in recent years TNF - α, IL-23, IL-17A are all kinds of "fairy fights" in clinical trials Stellara not only continues to defend the status of classic standard drugs for psoriasis, but also has a strong penetration of Crohn's disease market There are more than one million patients with Crohn's disease in the United States Previously, they were mainly treated with TNF - α biological agents Stelara is the first biological product approved for Crohn's disease, which aims at IL-12 and IL-23, providing new treatment options for patients Tremfya (guselkumab) is an IL-23 monoclonal antibody and a new product that Johnson & Johnson attaches great importance to in the field of autoimmune diseases It forms the double insurance of the IL-23 product line of Johnson & Johnson Tremfya was first approved in the United States in July 2017 Currently, the approved indications are plaque psoriasis and psoriatic arthritis Thanks to the expansion of the entire market and Johnson & Johnson's aggressive pricing strategy, tremfya's sales have exceeded $1 billion At the end of 2019, tremfya has just been approved for listing in China In the field of tumor, Johnson & Johnson is the leading enterprise of multiple myeloma After the brilliance of bortezomib, Johnson & Johnson now relies on darzalex (daratumab), which can provide the patients with multiple myeloma with the first-line to the end-line treatment scheme Since its first approval by FDA in November 2015, darzalex has become a blockbuster with sales volume of 3 billion US dollars in only four years The growth rate in 2019 is still nearly 50%, and it is expected to be among the top 10 best-selling drugs in the world in the next few years Multiple bone marrow can't be cured The patients show repeated relapse and remission They often have to go through multiple line therapy In addition, the patients have a large population, which provides impetus for the long-term growth of darzalex At the same time, BCMA car-t therapy in Johnson & Johnson's pipeline can serve as the last barrier for patients with relapse after receiving CD38 mAb treatment However, it is worth noting that Sanofi's CD38 McAb isatuximab has submitted an application for listing, and may break darzalex's exclusive market situation in 2020 Imbruvica's market rights outside the U.S belong to Johnson & Johnson In 2019, imbruvica brought us $3.4 billion in sales revenue to Johnson & Johnson, an increase of 30% over the same period last year This achievement is mainly due to the penetration of ibudinib in the first-line CLL indications Ibudinib is facing increasing market competition pressure, and the follow-up products all have the ambition to directly Ko ibudinib as the best in class, but so far, the head-on data of CLL has not been published, and 2020 should be a better year for ibudinib There are several other products of Johnson & Johnson that are not very friendly Zytiga (abitelon) has begun to encounter a patent cliff in the international market, while in the Chinese market, it has been besieged by generic pharmaceutical manufacturers In the just concluded volume purchase, Zhengda Tianqing, Hengrui and Shanxiang of Jiangxi will eliminate Johnson & Johnson In the future, we should place our hope in the field of prostate cancer in erlada (apalutamide) Xarelto, an anticoagulant, has been suppressed by apixaban, and sglt-2 inhibitors have enjoyed great success in the past year However, the distance between kaglitazine and its competitors has become more and more far In general, Johnson & Johnson's performance in 2019 is relatively stable, mainly relying on the new drugs darzalex, imbruvica and tremfya which have been launched in the past few years to stabilize the situation, making up for the decline of other products after the deterioration of market competition.